Atypia detected during breast screening and subsequent development of cancer: observational analysis of the Sloane atypia prospective cohort in England.
Author
Freeman, KarolineJenkinson, David
Clements, Karen
Wallis, Matthew G
Pinder, Sarah E
Provenzano, Elena
Stobart, Hilary
Stallard, Nigel
Kearins, Olive
Sharma, Nisha
Shaaban, Abeer
Kirwan, Cliona Clare
Hilton, Bridget
Thompson, Alastair M
Taylor-Phillips, Sian
Publication date
2024-02-01
Metadata
Show full item recordAbstract
There was a fourfold increase in detection of atypia after the introduction of digital mammography between 2010 (n=119) and 2015 (n=502). During 19 088 person years of follow-up after atypia diagnosis (until December 2018), 141 women developed breast cancer. Cumulative incidence of cancer per 1000 women with atypia was 0.95 (95% confidence interval 0.28 to 2.69), 14.2 (10.3 to 19.1), and 45.0 (36.3 to 55.1) at one, three, and six years after atypia diagnosis, respectively. Women with atypia detected more recently have lower rates of subsequent cancers detected within three years (6.0 invasive cancers per 1000 women (95% confidence interval 3.1 to 10.9) in 2013-18 v 24.3 (13.7 to 40.1) in 2003-07, and 24.6 (14.9 to 38.3) in 2008-12). Grade, size, and nodal involvement of subsequent invasive cancers were similar to those of cancers detected in the general screening population, with equal numbers of ipsilateral and contralateral cancers.Citation
Freeman K, Jenkinson D, Clements K, Wallis MG, Pinder SE, Provenzano E, Stobart H, Stallard N, Kearins O, Sharma N, Shaaban A, Kirwan CC, Hilton B, Thompson AM, Taylor-Phillips S; Sloane Project Steering Group. Atypia detected during breast screening and subsequent development of cancer: observational analysis of the Sloane atypia prospective cohort in England. BMJ. 2024 Feb 1;384:e077039. doi: 10.1136/bmj-2023-077039.Type
ArticleAdditional Links
http://www.bmj.com/thebmjPMID
38302129Journal
BMJ (Clinical Research ed.)Publisher
British Medical Associationae974a485f413a2113503eed53cd6c53
10.1136/bmj-2023-077039